Flagship to Present Computational Tissue Analysis Solutions for Advancing Drug Development at AACR Annual Meeting

Download Flagship AACR reference Westminster, CO, April 12, 2018 – Flagship Biosciences’ cTA® and decision support platform will be featured in four scientific poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 14-18, 2018, in Chicago. As the leading partner for drug developers investigating tissue-based biomarkers, Flagship applies computational tissue analysis […]

Read More

Flagship Receives Accreditation from College of American Pathologists

Westminster, CO, April 10, 2018 – The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Flagship Biosciences, based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs. “CAP accreditation validates Flagship’s commitment and dedication to ensuring the highest quality for our clients and patients,” says […]

Read More

Flagship Biosciences ActionAnalysis Solutions Accelerate Drug Development

Ready-to-use and custom image analysis meets current and future development needs Westminster, CO, February 12, 2018 – Flagship Biosciences is adding to its menu of ready-to-use image solutions with the introduction of ActionAnalysisTM. As the most experienced, integrated clinical laboratory, Flagship’s ActionAnalysis solutions help drug developers rapidly evaluate existing targets to define a biomarker-driven path […]

Read More

Flagship supports Summit Therapeutics advancement of DMD therapies

January 26, 2018 – Flagship is proud to partner with Summit Therapeutics in its efforts to advance therapies for patients with Duchenne Muscular Dystrophy (DMD). Summit Therapeutics issued a news release disclosing the interim results from its DMD phase II clinical trial, PhaseOut DMD. The endpoints reported by Flagship for these efforts are the first […]

Read More

Flagship Biosciences ActionAssays Deliver Actionable Data to Drive Immuno-Oncology Decisions

Comprehensive catalog of assays advance biomarker programs Westminster, CO, January 16, 2018 – Flagship Biosciences has introduced a new menu of services to help drug developers more confidently define their path to success. ActionAssaysTM is a comprehensive catalog of brightfield immunohistochemistry (IHC) assays that provide actionable data to define and advance biomarker programs. ActionAssays includes […]

Read More

Flagship Biosciences Presents PD-L1 Scoring Method at SITC 2017 that could Eliminate Reliance on Complex Multiplex IHC Assays

Novel cTA™-based morphometric biomarker interpretation approach quantifies immune cells in tumor tissues and has potential to revolutionize PD-L1 diagnostics landscape National Harbor, MD – November 11th 2017 – Flagship Biosciences, Inc., the leading developer of quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics to drive clinical decisions for industry partners, presented data today […]

Read More

Flagship Biosciences, Inc. Receives Prestigious Best Research Award for Poster on PD-L1 Harmonization at Pathology Visions 2017 Conference

Westminster, CO, Oct. 4, 2017 – Flagship Biosciences was honored to receive the award for Best Poster in the Research Category at the Pathology Visions 2017 annual conference in San Diego, CA for their poster on Evaluating Image Analysis Approaches Toward “Harmonization” of PD-L1 Assays. The poster describes how Flagships’ proprietary Computational Tissue Analysis (cTA™) […]

Read More

Flagship Biosciences Provides Analytically Validated Tools to Assist in the Analysis of Summit’s PhaseOut DMD Clinical Trial

CLSI compliant analytically validated cTA™ tools for 2 duplex IHC assays presented at the 22nd annual meeting of the World Muscle Society St. Malo, France, October, 5th, 2017 – Flagship Biosciences, Inc., the leading developer of quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics to drive clinical decisions for industry partners, presented today […]

Read More

Flagship Biosciences to Present at the Next Generation Dx Summit

Get the Whole Picture with both Content and Context August 9, 2017 – Westminster, CO – Flagship Biosciences, the leading partner for drug developers investigating tissue-based biomarkers, announced today that they will be a significant contributor to the strategic and scientific dialogue at the Next Generation Dx Summit in Washington DC, August 14th – 16th. […]

Read More

Flagship Biosciences’ support of Summit Therapeutics highlighted at the 2017 Needham Healthcare Conference

Glyn Edwards, CEO of Summit Therapeutics, plc and speaker at the Needham Healthcare Conference, highlighted the work that Flagship Biosciences is doing to support automated analyses of muscle biopsies in Summit’s on-going Phase 2 clinical trial for DMD. These analyses have the potential to support proof of concept for Summit’s utrophin modulator, ezutromid. In response […]

Read More